Understanding why patients with blood cancers may not take their oral cancer medications as prescribed
Official title: Identifying Multi-Level Predictors and Outcomes of Oral Anticancer Medication Adherence Initiation and Persistence among Patients with Hematologic Malignancies
Funded at University of Pittsburgh at Pittsburgh · NIH-10942408 · Data updated 2026-11-12
This study is looking at what helps or hinders patients with blood cancers, like multiple myeloma and chronic lymphocytic leukemia, from starting and sticking to their oral cancer medications, so we can find better ways to support them and improve their health and quality of life.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pittsburgh at Pittsburgh NIH-funded |
| Lab location | 1 site (Pittsburgh, United States) |
| Project start | August 1, 2024 |
| Project end | July 31, 2029 |
| Funding year | 2024 |
| Award (this year) | $656,560 |
| NIH project number | 1R01CA292925-01 |
| Project ID | NIH-10942408 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with hematologic malignancies who are prescribed oral anticancer medications.
✕Less likely to help
Patients who are not prescribed oral anticancer medications or those with non-hematologic cancers may not benefit from this research.
What this research studies
This research investigates the factors that influence whether patients with hematologic malignancies, such as multiple myeloma and chronic lymphocytic leukemia, start and continue taking their prescribed oral anticancer medications. By examining various influences on medication adherence, including personal, social, and systemic factors, the study aims to identify why some patients struggle with adherence. The research will analyze patient data to categorize adherence patterns and understand the impact of these patterns on health outcomes, particularly focusing on racial and ethnic differences. The goal is to develop strategies to improve adherence and ultimately enhance patient quality of life.
Why it matters
Potential benefit: If successful, this research could lead to improved strategies for ensuring patients take their oral cancer medications as prescribed, potentially enhancing treatment outcomes.
How similar studies have gone: Previous research has shown that addressing medication adherence in chronic conditions can lead to significant improvements in patient outcomes, suggesting that this approach may also be effective for hematologic malignancies.
Where this research is happening
-
University of Pittsburgh at Pittsburgh
Pittsburgh, United States Active
Researchers
- Principal investigator: Belcher, Sarah M. — University of Pittsburgh at Pittsburgh
- Study coordinator: Belcher, Sarah M.
Related research
Other NIH-funded projects on the same topics.
-
Understanding why patients with blood cancers start and stick with oral cancer medicines
A study to learn what helps or hinders Black patients with blood cancers in starting and continuing their prescribed oral cancer medicines.
-
What helps people with blood cancers start and keep taking oral cancer medicines
This project looks at why people with blood cancers (like CLL, CML, and multiple myeloma) do or don't start and stick with prescribed oral cancer medicines.
-
Adapting flow cytometry to detect childhood leukemias in Kenya using a single-test screen
A low-cost, blood-based flow cytometry screen in Kenya aims to detect and triage suspected leukemias in children and young adults.
-
Incentives and Anchoring to Improve Long-term HIV Medication Adherence
A study tests a simple, daily habit plan combined with friendly reminders and small rewards to help people living with HIV take their ART pills on time.
-
WeCare: a combined mental health and HIV medication support program for high-risk men
A patient-friendly program called WeCare aims to support mental health and improve adherence to HIV meds among high-risk men in settings with limited resources.
-
Why some blood cancer cells survive after treatment by resisting natural killer cells
This work is trying to understand why leftover blood cancer cells in leukemia and multiple myeloma survive treatment by escaping natural killer immune cells.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.